10times
16 Jun 2021

Exploring Future Applications of HER2/3 - Targeted Therapies Across Multiple Tumor Types

AboutSpeakersExhibitorsReviewsPhotos

Timings

09:00 AM - 06:00 PM
Not Verified

Official Links

Estimated Turnout

upto 100
Delegates
Based on previous editions

Editions

Jun 2021
+1 more edition

Frequency

Annual
Claim event to edit details

Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing .. Read more medical education for physicians. For over 20 years, trastuzumab has been the foundation of therapy for patients with human epidermal growth factor receptor 2 (HER2)-positive breast cancer. HER2 and HER3 amplification have been increasingly recognized as a frequent abnormality in not only gastric cancer, but also gastroesophageal and colorectal cancers, enabling oncologists to administer HER2/3-targeted therapies to these patients as well. While EGFR, another receptor related to HER2, has long been a target successfully treated in patients with non–small-cell lung cancer, novel anti-HER2 agents have emerged to combat tumor resistance. This archived webcast, featuring an expert faculty panel of medical oncologists across tumor types, will dive deep into the latest available data on HER2/3-targeted treatment strategies for patients with breast, gastrointestinal (GI), and lung cancers. This activity will share best practices for incorporating key data from landmark clinical trials of HER2-positive cancers into the everyday clinic and will review emerging novel anti-HER2/3 agents under investigation. This educational activity is directed toward medical oncologists, pathologists, radiation oncologists, and surgical oncologists interested in the treatment of cancer.

  • Share your Experience
  • Organizer
LogoRequest a Booth

Physicians Education ResourceRenowned

USA107 Total Events / 72 Upcoming Events

More Events From The Organizer